SHANGHAI, April 16, 2025 /PRNewswire/ -- On April 15, 2025, Henlius (2696.HK) proudly announced the release of its "2024 Environmental, Social, and Governance (ESG) Report". This report marks a significant milestone as it is the sixth consecutive year the biopharmaceutical company has delivered an ESG-related report to its global stakeholders. The Report comprehensively highlights Henlius' notable achievements and unwavering commitment across five critical ESG pillars: Product, Talent, Environment, Society, and Corporate Governance.

Together for Health

Prioritizing patient needs, Henlius has consistently ramped up its research and development (R&D) capabilities. In 2024, the company allocated an impressive RMB1.8405 billion to R&D. To date, Henlius has successfully launched six innovative products across approximately 50 countries and regions, positively impacting the lives of over 750,000 patients. The company strategically focuses on therapeutic areas such as oncology and autoimmune diseases, boasting a rapidly advancing pipeline of around 50 molecules. Notably, Henlius has achieved extensive coverage in high-incidence cancers including lung cancer, colorectal cancer, gastric cancer, and esophageal squamous cell carcinoma. Moreover, it is actively engaged in the development of five orphan drugs aimed at treating rare diseases across various therapeutic areas including oncology, chronic inflammatory conditions, and neurological diseases.

In a bid to enhance access to healthcare, five of Henlius' products have been included in China's National Reimbursement Drug List (NRDL). The trastuzumab biosimilar HANQUYOU has been embraced by public health insurance systems in several countries, including China, the UK, France, and Germany. Additionally, the PD-1 inhibitor HANSIZHUANG has found its place in 118 provincial or municipal-level government-backed supplemental insurance programs (Huiminbao), significantly improving access to high-quality biologics. Furthermore, through fruitful collaborations with international partners like Abbott and SVAX, Henlius is making strides in emerging markets such as Latin America and the Middle East, thereby introducing Chinese innovations to the global healthcare landscape.

Together for Talent Growth

In alignment with its people-centric talent philosophy, Henlius is dedicated to cultivating a diverse talent ecosystem. In 2024, women constituted an impressive 53% of the workforce. The company has implemented a Diversity Policy and launched an internal communication platform known as "H-Voice" to foster open and transparent dialogue among employees. Henlius remains committed to supporting employee growth and development, providing assistance to 144 employees in obtaining professional certifications. With the advent of the online learning platform "Henlius Academy" and tailored training programs, the company is steadfastly enhancing its talent pipeline and empowering future development. On average, employees received 70.37 hours of training in 2024. That same year, Henlius was recognized as one of HR Asia's Best Companies to Work for in Asia for the third consecutive year, and it also earned the title of one of Universum's Most Attractive Employers for Chinese Students for the first time.

Together for a Green Future

Recognizing the significance of sustainable development, Henlius integrates environmental protection into its core values and operational practices. In 2024, the company invested RMB7.8445 million in environmental initiatives, reflecting a 26% increase year-over-year and demonstrating its robust commitment to environmental sustainability. Throughout the year, Henlius completed 230 lean improvement projects, achieving a 2.87% reduction in comprehensive energy consumption, a 5.47% decrease in greenhouse gas emissions, and a 5.93% reduction in water consumption. These efforts contribute to promoting cleaner air and water. The Songjiang Facility successfully obtained ISO 14001:2015 certification for its environmental management system, reinforcing its adherence to international environmental standards. Additionally, Henlius has advanced green supply chain initiatives, with 80% of direct procurement suppliers entering into agreements to promote green practices, collaboratively driving low-carbon transformation across the industry.

Together for a Thriving Community

Guided by its "patient-centric" public welfare philosophy, Henlius has implemented numerous social care initiatives in 2024, with total charitable donations amounting to RMB134.84 million. The company has continued its Breast Cancer Rural Healthcare Outreach Program and organized public awareness activities for breast cancer, as well as International Lung Cancer Awareness Month. These efforts included a charity cycling event aimed at promoting healthy lifestyles and comprehensive patient care.

In terms of supply chain management, Henlius has adopted Business Intelligence (BI) systems to enhance transparency. Remarkably, 80% of its local suppliers have been integrated into its Good Manufacturing Practice (GMP) system, resulting in approximately RMB55.65 million in procurement savings. These ongoing efforts drive cost reductions, improve efficiency, and bolster the stability of the supply chain.

Together for Stronger Governance

Henlius has built its ESG strategy on a solid foundation of compliance and governance, supported by a comprehensive four-tier ESG governance framework. In 2024, the company hosted two dedicated ESG meetings and launched its inaugural company-wide ESG Culture Month, further embedding ESG practices into its operational framework. Henlius remains committed to responsible operations, conducting 99 compliance training sessions that engaged a total of 4,569 participants, with 100% of employees signing the Compliance Commitment Letter. The commercial team underwent targeted responsible marketing training through 39 sessions, which attracted 4,867 participants. In 2024, Henlius filed 22 patent applications and secured 10 grants for invention or utility model patents. Additionally, the company successfully passed recertification for ISO 27001:2022, reinforcing its commitment to information security management.

Driven by innovation, with accessibility as the primary goal, sustainability as the foundation, social responsibility as the motivating force, and governance as the safeguard, Henlius is dedicated to continuously creating value for patients, employees, society, and the industry at large. Looking ahead, the company remains committed to its patient-centered mission, integrating ESG principles into its business development, and contributing significantly to global health, all while striving to co-create a brighter future for human well-being.

About Henlius

Henlius (2696.HK) is a leading global biopharmaceutical company with the vision of providing high-quality, affordable, and innovative biologic medicines to patients worldwide. The company focuses on therapeutic areas such as oncology, autoimmune diseases, and ophthalmic conditions. As of now, Henlius has launched six products in China, four of which have received marketing approval in international markets. Furthermore, five marketing applications have been accepted for review in China, the U.S., and the European Union. Since its establishment in 2010, Henlius has built an integrated biopharmaceutical platform that encompasses high-efficiency and innovation throughout the entire product lifecycle, including R&D, manufacturing, and commercialization. The company operates global innovation centers and Shanghai-based commercial manufacturing facilities certified by China, the EU, and U.S. Good Manufacturing Practices (GMP).

Henlius has proactively developed a diversified and high-quality product pipeline, encompassing approximately 50 molecules, and continues to explore immuno-oncology combination therapies with its proprietary anti-PD-1 monoclonal antibody, HANSIZHUANG, serving as the backbone. To date, Henlius' launched products include HANLIKANG (rituximab), the first biosimilar developed in China, HANQUYOU (trastuzumab, marketed as HERCESSI in the U.S. and Zercepac in Europe), a China-developed monoclonal antibody biosimilar approved in both domestic and international markets, HANDAYUAN (adalimumab), HANBEITAI (bevacizumab), HANSIZHUANG (serplulimab, marketed as Hetronifly in Europe), the world's first anti-PD-1 monoclonal antibody approved for the first-line treatment of small cell lung cancer, and HANNAIJIA (neratinib). Furthermore, Henlius has conducted over 30 clinical studies for 19 products, expanding its footprint in major markets as well as emerging markets.

SOURCE Henlius